For example, patients with EGFR mutant adenocarcinoma lung cancer (a type of NSCLC) treated with EGFR-TKI have been reported to achieve long-term survival while maintaining good performance status [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.